Scribe Therapeutics (NASDAQ:SCTX) Releases Earnings Results, Beats Estimates By $2.36 EPS

Scribe Therapeutics (NASDAQ:SCTX) announced its earnings results on Wednesday. The company reported ($3.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.20) by $2.36, Zacks reports.

Scribe Therapeutics Stock Up 6.6%

Shares of NASDAQ SCTX traded up $1.90 during mid-day trading on Wednesday, reaching $30.90. The company had a trading volume of 278,607 shares, compared to its average volume of 232,297. Scribe Therapeutics has a twelve month low of $17.31 and a twelve month high of $39.60.

Insider Transactions at Scribe Therapeutics

In other news, major shareholder Bio Fund Ii L.P. Ah bought 333,333 shares of the company’s stock in a transaction on Monday, July 27th. The shares were bought at an average cost of $15.00 per share, with a total value of $4,999,995.00. Following the transaction, the insider directly owned 2,385,075 shares in the company, valued at approximately $35,776,125. This trade represents a 16.25% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Behzad Aghazadeh purchased 7,905 shares of the business’s stock in a transaction dated Tuesday, July 28th. The shares were purchased at an average cost of $18.25 per share, with a total value of $144,266.25. Following the completion of the purchase, the director directly owned 3,088,888 shares in the company, valued at approximately $56,372,206. This represents a 0.26% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 3,727,237 shares of company stock worth $56,291,746 in the last ninety days.

Key Scribe Therapeutics News

Here are the key news stories impacting Scribe Therapeutics this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $60 price target, implying considerable upside from recent trading levels. The firm’s coverage provides a new bullish valuation reference for the clinical-stage biotechnology company. HC Wainwright Begins Coverage on Scribe Therapeutics
• Positive Sentiment: HC Wainwright expects Scribe’s quarterly losses to narrow after the second quarter of 2026, forecasting EPS of negative $1.02 in Q3 2026 and negative $1.05 in Q4 2026, compared with negative $6.20 in Q2 2026. The firm projects a negative $4.90 EPS loss for fiscal 2027, better than its negative $6.72 forecast for fiscal 2026.
• Neutral Sentiment: Management will participate in upcoming investor conferences, including the Wells Fargo Healthcare Conference. These events could provide updates on Scribe’s in vivo CRISPR pipeline, but no new clinical, regulatory, or financial data was announced. Scribe Therapeutics to Participate in Upcoming Investor Conferences
• Negative Sentiment: Despite the bullish rating, HC Wainwright still forecasts sizable losses across every listed period, including negative $1.10 to negative $1.36 EPS in the first four quarters of 2027. Continued losses and the absence of reported clinical or partnership developments remain risks for SCTX investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on SCTX shares. Wells Fargo & Company initiated coverage on Scribe Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $60.00 price target on the stock. HC Wainwright initiated coverage on shares of Scribe Therapeutics in a research report on Monday. They issued a “buy” rating and a $60.00 price target for the company. Wall Street Zen raised shares of Scribe Therapeutics to a “hold” rating in a research note on Saturday, August 1st. Leerink Partners assumed coverage on shares of Scribe Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating and a $37.00 target price on the stock. Finally, Guggenheim assumed coverage on Scribe Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $50.00 target price for the company. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $51.75.

About Scribe Therapeutics

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.